As on 01-Dec-2023 IST
₹1,212.30
₹1,213.45
₹1,217.85
₹1,203.50
10,78,680
₹852.00 - 1,283.55
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Cipla
| 12.06 | 0.48 | -4.13 | 5.80 | 17.38 | 17.39 | 11.91 |
S&P BSE Sensex
| 10.91 | 5.65 | 4.09 | 6.94 | 15.19 | 13.27 | 12.49 |
S&P BSE Healthcare
| 32.32 | 11.76 | 9.26 | 27.28 | 14.47 | 16.29 | 12.36 |
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
---|---|---|---|---|---|---|---|
Cipla
| 13.97 | 14.21 | 72.29 | -8.57 | -15.04 | 6.98 | -13.21 |
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
S&P BSE Healthcare
| -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 | -12.88 |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
Stock
|
Peer Median
|
||
---|---|---|---|
Please wait... |
The total asset value of Cipla Ltd. stood at ₹ 31,377 Cr as on 30-Sep-23
The share price of Cipla Ltd. is ₹1,205.70 (NSE) and ₹1,206.65 (BSE) as of 01-Dec-2023 IST. Cipla Ltd. has given a return of 17.38% in the last 3 years.
Cipla Ltd. has a market capitalisation of ₹ 97,419 Cr as on 01-Dec-2023. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Cipla Ltd. is 3.92 times as on 01-Dec-2023, a 0.2% premium to its peers’ median range of 3.28 times.
The P/E ratio of Cipla Ltd. is 28.21 times as on 01-Dec-2023, a -0.06% premium to its peers’ median range of 30.01 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cipla Ltd. and enter the required number of quantities and click on buy to purchase the shares of Cipla Ltd..
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
The prominent promoters of Cipla Ltd. are
Name of promoters | Holding percentage |
---|---|
Yusuf Khwaja Hameid |
18.68%
|
Sophie Ahmed |
5.71%
|
Mustafa Khwaja Hamied |
3.46%
|
The chairman of the company is Y K Hamied, and the managing director is Umang Vohra.
The promoters of Cipla Ltd. have pledged 0% of the total equity as on Sep-23.
Some of the close peers are:
Company | Market Cap(₹ Cr) |
---|---|
2,95,418
|
|
1,00,675
|
|
95,867
|
|
72,810
|
Cipla Ltd. | Ratios |
---|---|
Return on equity(%)
|
14.85
|
Return on capital employed(%)
|
--
|
Debt-to-equity ratio
|
0
|
Dividend yield(%)
|
0.7
|
Yes, TTM profit after tax of Cipla Ltd. was ₹3,453 Cr.
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also... offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India. Read more
Sign up and get access to:
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.